November 28, 2022

Phase 2 trial of AD-35 for mild to moderate Alzheimer’s is in progress

Zhejiang Hisun Pharmaceutical Co. Ltd. in collaboration with Medspace, Inc., is conducting a trial of AD-35’s effectiveness for Mild to Moderate Alzheimer’s since October 4, 2018 and will continue till July 31, 2020.

This trial will test the safety, tolerability, and effects of AD-35 on cognitive function in older adults with mild to moderate Alzheimer’s disease.

What’s AD-35?

AD-35 is small-molecule compound being investigated for the treatment and prevention of Alzheimer’s disease. Earlier research shows the compound may inhibit aggregation of amyloid-beta, a protein that accumulates abnormally in Alzheimer’s disease.

Find out whether you or your loved one is eligible for the trial: https://www.nia.nih.gov/alzheimers/clinical-trials/ad-35-mild-moderate-alzheimers

Leave a Reply

Your email address will not be published. Required fields are marked *

Hey there!
Would you like to be notified when we publish new content?

You have successfully subscribed

There was an error while trying to send your request. Please try again.

Hopeful Trials & News will use the information you provide on this form to be in touch with you and to provide updates and marketing.